GeNeuro: Half-Yearly Report on the Liquidity Contract with Gilbert Dupont

Regulatory News:

Pursuant to the liquidity contract entrusted by GeNeuro SA (Paris:GNRO) to Gilbert Dupont, as of June 30, 2016, the following assets appeared on the liquidity account:

- Number of shares: 50,212

- Cash balance of the liquidity account: € 253,003.06

As a reminder, when the contract was implemented, the following resources were booked to the liquidity account:

- Number of shares: 0

- Cash balance of the liquidity account: €750,000.00

About GeNeuro

GeNeuro‘s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases such as multiple sclerosis by neutralizing causal factors encoded by human endogenous retroviruses (HERV), which represent 8% of the human DNA; a new frontier pioneered by GeNeuro since 2006 based on 15 years of R&D at Institut Mérieux and INSERM.

GeNeuro is based in Geneva, Switzerland and has R&D facilities in Archamps, Haute-Savoie and Lyon. It has 23 employees and rights to 16 patent families protecting its technology.

For more information, visit: www.geneuro.com

Market: Euronext Paris
ISIN code / Mnemo: CH0308403085 / GNRO
Web site: www.geneuro.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20160704005403/en/